Tag Archives: Nektar Therapeutics

November, 2018

May, 2018

  • 31 May

    Syndax and Nektar Therapeutics Partner for Immuno-Oncology Clinical Trial

    WALTHAM, Mass. and SAN FRANCISCO, May 30, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) today announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar’s NKTR-214, a CD122-biased agonist, …

April, 2018

July, 2017

May, 2017

March, 2015

  • 18 March

    Nektar’s Breast Cancer Drug Fails its Late-Stage Trial

    Nektar Therapeutics’ experimental breast cancer drug, and key to the company’s future growth, failed a late-stage study. The company said that its NKTR-102 failed to meet its primary endpoint in the Phase III BEACON study. The drug is considered key to the Nektar’s future growth. The company’s CEO Howard Robin …